ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TYR Tyratech (DI/S)

2.95
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tyratech (DI/S) LSE:TYR London Ordinary Share COM SHS USD0.001 (DI / REGS)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.95 2.70 3.20 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

TyraTech, Inc. French Registration of Insect Repellent Product (0767C)

11/04/2013 7:00am

UK Regulatory


Tyratech (LSE:TYR)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Tyratech Charts.

TIDMTYR TIDMTYRU

RNS Number : 0767C

TyraTech, Inc.

11 April 2013

11 April 2013

TyraTech, Inc.

(the "Company" or "TyraTech")

French Registration of Insect Repellent Product TyraTech Naturals(R)

Field Trials Demonstrate Superior Performance Over Current Market-Leading Products

TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that the Company has been granted registration for its new personal insect repellent in France. This means that the product is approved and ready for immediate commercialisation in retail channels. The personal insect repellent features TyraTech's Nature's Technology(TM) platform which harnesses the power of natural ingredients to deliver best-in-class efficacy and family safety.

Both Laboratory and Field trials have demonstrated that the personal insect repellent significantly outperforms 15% DEET for both mosquito and tick repellency (DEET being the most common active ingredient in insect repellents). Trials have been carried out using various species of mosquito including those which are known vectors of West Nile Virus, Malaria, Dengue fever, yellow fever and St Louis encephalitis. Tick trials have included species which are vectors for Lyme disease, Rocky Mountain spotted fever and Southern tick associated rash infection (STARI).

The Company has filed for patent protection for its personal insect repellent formulation and has submitted data from the laboratory and field trials for publication in two international journals. The Company has already been granted registrations for its personal insect repellent in the U.S., German and UK markets.

Bruno Jactel, Chief Executive of TyraTech, commented: "TyraTech's personal insect repellent provides an effective and timely solution for families seeking superior protection without concerns over safety. Our portfolio of European registrations is expected to continue to grow in the coming months. We are currently in the process of evaluating commercial and retail partners for this product and our other products."

Further information on TyraTech's personal insect repellent is available on the Company's website at www.tyratech.com/RepellentTechnologyOverview

For further information please contact:

TyraTech Inc.

Alan Reade, Executive Chairman

Tel: +1 919 415 4310

Bruno Jactel, Chief Executive Officer

Tel: +1 919 415 4340

N+1 Singer, Nominated Adviser and Joint Broker

Aubrey Powell / Alex Wright

Tel: +44 20 7496 3000

First Columbus LLP, Joint Broker

Chris Crawford

Tel: +44 20 3002 2070

Walbrook, Financial PR and IR

Bob Huxford/ Paul Cornelius

Tel + 44 20 7933 8792

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUROKROAASAAR

1 Year Tyratech Chart

1 Year Tyratech Chart

1 Month Tyratech Chart

1 Month Tyratech Chart

Your Recent History

Delayed Upgrade Clock